Fenofibrate
NDC Package 0115-0522-01

11-digit billing NDC: 00115052201 · Billing unit: EA · 100 EA per package

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was inactivated by the FDA.

Fenofibrate is treatment of HypercholesterolemiaFenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Marketed by Amneal Pharmaceuticals Of New York Llc, this product is identified by NDC 0115-0522 and is authorized under FDA application ANDA075868.

Identification & Billing

NDC Package Code
0115-0522-01
Package Description
100 CAPSULE in 1 BOTTLE
Product Code
11-Digit Billing Format
00115052201
Billing Unit
EA - Billing unit of "each" is used when the product is dispensed in discreet units.
Units Per Package
100 EA
RxNorm Crosswalk

Clinical Specifications

Proprietary Name
Fenofibrate
Dosage Form
-
Usage Information
Treatment of HypercholesterolemiaFenofibrate capsules are indicated as adjunctive therapy to diet for the reduction of LDL-C, Total-C, Triglycerides and Apo B in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Lipid-altering agents should be used in addition to a diet restricted in saturated fat and cholesterol when response to diet and non-pharmacological interventions alone has been inadequate (see National Cholesterol Education Program [NCEP] Treatment Guidelines, below).Treatment of HypertriglyceridemiaFenofibrate capsules are also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia).Improving glycemic control in diabetic patients showing fasting chylomicronemia will usually reduce fasting triglycerides and eliminate chylomicronemia thereby obviating the need for pharmacologic intervention.Markedly elevated levels of serum triglycerides (e.g., > 2,000 mg/dL) may increase the risk of developing pancreatitis. The effect of fenofibrate therapy on reducing this risk has not been adequately studied.Drug therapy is not indicated for patients with Type I hyperlipoproteinemia, who have elevations of chylomicrons and plasma triglycerides, but who have normal levels of very low density lipoprotein (VLDL). Inspection of plasma refrigerated for 14 hours is helpful in distinguishing Types I, IV and V hyperlipoproteinemia2.The initial treatment for dyslipidemia is dietary therapy specific for the type of lipoprotein abnormality. Excess body weight and excess alcoholic intake may be important factors in hypertriglyceridemia and should be addressed prior to any drug therapy. Physical exercise can be an important ancillary measure. Diseases contributory to hyperlipidemia, such as hypothyroidism or diabetes mellitus should be looked for and adequately treated. Estrogen therapy, like thiazide diuretics and beta-blockers, is sometimes associated with massive rises in plasma triglycerides, especially in subjects with familial hypertriglyceridemia. In such cases, discontinuation of the specific etiologic agent may obviate the need for specific drug therapy of hypertriglyceridemia.The use of drugs should be considered only when reasonable attempts have been made to obtain satisfactory results with non-drug methods. If the decision is made to use drugs, the patient should be instructed that this does not reduce the importance of adhering to diet (see WARNINGS and PRECAUTIONS).Fredrickson Classification of HyperlipoproteinemiasTypeLipoprotein ElevatedLipid ElevationMajorMinorI (rare)ChylomicronsTG↑↔CIIaLDLC—IIbLDL, VLDLCTGIII (rare)IDLC, TG—IVVLDLTG↑↔CV (rare)Chylomicrons, VLDLTG↑↔C = cholesterolTG = triglyceridesLDL = low density lipoproteinVLDL = very low density lipoproteinIDL = intermediate density lipoproteinThe NCEP Treatment GuidelinesDefinite Athlerosclerotic DiseaseaTwo or More Other Risk FactorsbLDL-Cholesterol mg/dL (mmol/L)Initiation LevelGoalNoNo≥ 190 (≥ 4.9)< 160 (< 4.1)NoYes≥ 160 (≥ 4.1)< 130 (< 3.4)YesYes or No≥ 130c (≥ 3.4)< 100 (< 2.6)aCoronary heart disease or peripheral vascular disease (including symptomatic carotid artery disease).b Other risk factors for coronary heart disease (CHD) include: age (males: ≥ 45 years; females: ≥ 55 years or premature menopause without estrogen replacement therapy); family history of premature CHD; current cigarette smoking; hypertension; confirmed HDL-C < 35 mg/dL (< 0.91mmol/L); and diabetes mellitus. Subtract 1 risk factor if HDL-C is ≥ 60 mg/dL (≥ 1.6 mmol/L)cIn CHD patients with LDL-C levels 100 to 129 mg/dL, the physician should exercise clinical judgment in deciding whether to initiate drug treatment.

Regulatory & Marketing

Labeler Name
Amneal Pharmaceuticals Of New York Llc
FDA Application #
ANDA075868
Marketing Category
ANDA - A product marketed under an approved Abbreviated New Drug Application.
Start Marketing Date
02-01-2010
Listing Expiration
12-31-2023
Exclude Flag
I
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Other Available Packages

The following commercial packages are registered under the same Product NDC (0115-0522). Click a package code to view its specific billing and regulatory data.

500 CAPSULE in 1 BOTTLE

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 0115-0522-01 identifies a specific commercial package of 100 capsule in 1 bottle of Fenofibrate, labeled by Amneal Pharmaceuticals Of New York Llc. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Amneal Pharmaceuticals Of New York Llc on February 01, 2010. The current certification is valid through December 31, 2023.

How is this Amneal Pharmaceuticals Of New York Llc product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 00115052201. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. There are 100 total billable units per package. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (4-4-2)
0115-0522-01
11-Digit CMS (5-4-2)
00115-0522-01

Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.